Fiche publication


Date publication

novembre 2023

Journal

ACS biomaterials science & engineering

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CLEYMAND Franck , Pr MANO João F.


Tous les auteurs :
Poerio A, Mano JF, Cleymand F

Résumé

The controlled delivery of growth factors (GFs) from tissue engineered constructs represents a promising strategy to improve tissue repair and regeneration. However, despite their established key role in tissue regeneration, the use of GFs is limited by their short half-life in the environment, their dose-dependent effectiveness, and their space- and time-dependent activity. Promising results have been obtained both and in animal models. Nevertheless, the clinical application of tissue engineered constructs releasing GFs is still challenging due to the several limitations and risks associated with their use. 3D printing and bioprinting, by allowing the microprecise spatial deposition of multiple materials and the fabrication of complex geometries with high resolution, offer advanced strategies for an optimal release of GFs from tissue engineered constructs. This review summarizes the strategies that have been employed to include GFs and their delivery system into biomaterials used for 3D printing applications to optimize their controlled release and to improve both the and regeneration processes. The approaches adopted to overcome the above-mentioned limitations are presented, showing the potential of the technology of 3D printing to get one step closer to clinical applications.

Mots clés

3D bioprinting, functionalized biomaterial inks, growth factors delivery strategies

Référence

ACS Biomater Sci Eng. 2023 11 15;: